Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
(WorldNews Business)

INDIANAPOLIS, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced grants of options to four new employees to purchase an aggregate of 10,400 shares of Assembly`s common stock with an exercise price of $44.28 per share, the closing price on December 8, 2017. The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in...